ChroniSense Medical, an Israeli medtech company, has developed a smartwatch that works as a wearable medical sensor.
It can accurately monitor vital signs like blood oxygen saturation, pulse rate and respiration rate. The device, called Polso, is designed for both home and clinical settings, and comes with a mobile app for patients, and a cloud-based platform for clinicians.
It ensures both continuous and spot-check patient monitoring, which frees caregivers from the tedious duty.
Recent studies demonstrated Polso’s accuracy and ease-of-use across demographic groups, and under-served patient populations. ChroniSense Medical is developing additional vital sign monitoring parameters – including blood pressure via an artery of the arm.
The device just received FDA clearance as being safe and effective.
“FDA clearance is a significant milestone towards the commercialization of Polso Connect and towards creating a new model in chronic care management,” said ChroniSense Medical CEO, Bridget Ross.
“With 6 out of 10 adults in the US living with a chronic condition, and over $1.1 trillion in direct healthcare costs annually, there is a serious need for an easy-to-use, medical grade, remote patient monitoring solution.”
Din Hadass, ChroniSense Medical GM, Israel, said: “FDA clearance is an important validation of our technology. ChroniSense Medical is laser-focused on bringing to market monitoring solutions that will revolutionize patient management, help save lives, and reduce the heavy cost burden of chronic care.”
ChroniSense Medical is based in Yokneam, northern Israel.